Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial compared tafasitamab plus bendamustine to rituximab plus bendamustine in adults with relapsed or refractory diffuse large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Incyte Corporation | Conditions: Diffuse Large B-cell Lymphoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-07-17